Epoetin alfa therapy for patients with hematologic malignancies and mild anemia

Clinical Lymphoma

Volumn 4, Issue SUPPL. 1, 2003, Pages

  Straus, David J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chronic lymphocytic leukemia; Hemoglobin; Human recombinant erythropoietin; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; HEMOGLOBIN DETERMINATION; HUMAN; LINEAR REGRESSION ANALYSIS; LYMPHOMA; MALE; MULTIPLE MYELOMA; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0142124302     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2003.s.003     Document Type: Article

References (35)

1. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997; 34:4-12.
2. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5:353-360.
3. Curt GA. Fatigue in cancer. BMJ 2001; 322:1560.
4. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91:2214-2221.
5. Riccardi A, Gobbi PG, Ucci G, et al. Changing clinical presentation of multiple myeloma. Eur J Cancer 1991; 27:1401-1405.
6. Littlewood TJ. Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematol Oncol 2001; 19:19-30.
7. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616-1634.
8. Coiffier B, Guastalla JP, Pujade-Lauraine E, et al. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 2001; 37:1617-1623.
9. Ludwig H, Birgegard G, Barrett-Lee P, et al. Prevalence and management of anemia in patients (pts) with hematologic malignancies (HMs) and solid tumors (STs): results from the European Cancer Anaemia Survey (ECAS). Blood 2002; 100(suppl):234a-235a (Abstract #884).
10. Birgegard G, Ludwig H, Nortier JW, et al. Despite high prevalence of anemia and impact on high performance status (PS), anemia treatment (Tx) rate is low in multiple myeloma/lymphoma (MM/L) patients (pts) according to European Cancer Anaemia Survey (ECAS). Blood 2002; 100 (suppl):18b (Abstract #3521).
11. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20:4083-4107.
12. Sabbatini P, Cella D, Chanan-Khan A, et al. Cancer and treatment related-anemia. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. V.1.2003, Rockledge, PA: National Comprehensive Cancer Network Inc., November 2002.
13. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15:1218-1234.
14. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16:3412-3425.
15. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875-2882.
16. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003. In press.
17. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001; 113:172-179.
18. Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002; 20:2486-2494.
19. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 1998; 103:1070-1074.
20. Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322:1693-1699.
21. Garton JP, Gertz MA, Witzig TE, et al. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 1995; 155:2069-2074.
22. Osterberg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996; 87:2675-2682.
23. Dammacco F, Silvestris F, Castoldi GL, et al. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 1998; 28:127-134.
24. Rose E, Rai K, Revicki D, et al. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated wtih epoetin alfa (EPO). Blood 1994; 84(suppl 1):526a (Abstract #2091).
25. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995; 86:4446-4453.
26. Niscola P, Scaramucci L, Menichelli L, et al. High-doses epoetin alpha in patients with multiple myeloma-related anaemia: early response and effective maintenance treatment with a longer survival. Haema 2003; 6:187-192.
27. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95:888-895.
28. Shasha D, George MJ, Harrison LB. Significant relationship between hemoglobin (Hb) level and quality of life (QOL) during chemoradiation: findings from an incremental analysis of a 442-patients prospective, community-based epoetin alfa study. Int J Radiat Oncol Biol Physics 2002; 54(suppl):48 (Abstract #78).
29. Cella D, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003; 21:366-373.
30. Patrick DL, Gagnon DD, Zagari MJ, et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003; 39:335-345.
31. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865-2874.
32. Sloan JA, Witzig TE, Silberstein P, et al. Quality of life, blood transfusions, and toxicity, in anemic patients with advanced cancer receiving weekly erythropoietin while on chemotherapy: results from a phase III randomized double-blind placebo-controlled study. Blood 2002; 11(suppl):287a (Abstract #1103).
33. Littlewood TJ, Nortier JW, Rapoport B, et al. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving nonplatinum chemotherapy. Hematol Oncol 2003. In press.
34. Fallowfield L, Gagnon D, Zagari M, et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002; 87:1341-1353.
35. Straus DJ, Turner RR, Testa MA, et al. Epoetin alfa treatment improves quality of life and increasese hemoglobin levels during chemotherapy for lymphoma, chronic lymphocyctic leukemia (CLL), and multiple myeloma (MM) patients with mild-to-moderate anemia. Blood 2002; 100(suppl):220a (Abstract #828).